63091-82-7

Basic information

• Product Name: BOC-D-THZ-OH
• Synonyms: BOC-D-THIOPRO-OH;BOC-D-THZ-OH;BOC-(S)-THIAZOLIDINE-4-CARBOXYLIC ACID;(S)-N-(TERT-BUTYLOXYCARBONYL)-THIAZOLIDINE-4-CARBOXYLIC ACID;N-ALPHA-T-BUTYLOXYCARBONYL-D-THIAZOLIDINE-4-CARBOXYLIC ACID;N-ALPHA-T-BUTOXYCARBONYL-D-THIAZOLIDINE-4-CARBOXYLIC ACID;N-ALPHA-T-BUTOXYCARBONYL-D-THIOPROLINE;N-tert-Butoxycarbonyl-D-hepalidine
• CAS NO: 63091-82-7
• Molecular Formula: C₉H₁₅NO₄S
• Molecular Weight: 233.28
• Product Categories: Amino Acids
• Mol File: 63091-82-7.mol

Chemical Properties

• Boiling Point: 385.3±42.0 °C(Predicted)
• Appearance: /
• Density: 1.305±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 3.53±0.20(Predicted)
• CAS DataBase Reference: BOC-D-THZ-OH(CAS DataBase Reference)
• NIST Chemistry Reference: BOC-D-THZ-OH(63091-82-7)
• EPA Substance Registry System: BOC-D-THZ-OH(63091-82-7)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 63091-82-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research:
BOC-D-THZ-OH is used as a building block in the synthesis of peptide and protein-based compounds for pharmaceutical research. It aids in the development of therapeutic agents and the study of peptide structure-activity relationships, contributing to the advancement of medicinal chemistry and drug discovery.
Used in Peptide Synthesis:
In the field of peptide synthesis, BOC-D-THZ-OH is utilized as a protected amino acid, facilitating the creation of complex peptide structures. Its protective group helps prevent unwanted side reactions during the synthesis process, ensuring the successful formation of the desired peptide sequences.
Used in Drug Production:
BOC-D-THZ-OH is employed in the production of pharmaceutical drugs, where it serves as a key component in the synthesis of various therapeutic agents. Its versatility and reactivity make it an essential tool in the development of new and effective medications.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 34592-47-7 L-thioproline 
• 444-27-9 L-thiaproline 

Downstream Products

• 104434-77-7 6-(4-(3-tert.-Butoxycarbonyl-L-thiazolidin-4-yl-carbonyl-amino)phenyl)-5-methyl-4,5-dihydro-3(2H)-pyridazinone 
• 425403-78-7 (S)-4-[(S)-2-(2'-Methoxy-biphenyl-4-yl)-1-methoxycarbonyl-ethylcarbamoyl]-thiazolidine-3-carboxylic acid tert-butyl ester 
• 739365-93-6 (4S)-3-(tert-Butyloxycarbonyl)thiazolidine-4-carboxamide 
• 229328-24-9 C₂₆H₂₉Cl₂N₃O₆S 
• 1318780-42-5 C₂₂H₃₃N₃O₆S 
• 1318780-43-6 C₃₀H₃₉N₃O₈S 
• 397867-84-4 methyl N-benzoyl-N-[piperidin-4-yl-N-(N-Boc-(S)-thiazolidine-4-carbonyl)]-(S)-methioninate 

Relevant articles and documents

BENZIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING BENZIDINE DERIVATIVE FOR TREATING LIVER DISEASE CAUSED BY HEPATITIS C VIRUS

The disclosed compounds have antiviral activity against C-type virus, an optical isomer thereof, a pharmaceutically acceptable salt thereof, a method for preparing the same, and a pharmaceutical composition containing the same as an active ingredient for preventing or treating liver disease caused by hepatitis C virus. The benzidine derivative according to the present invention has excellent antiviral activity against hepatitis C virus and exhibits excellent medicinal activity in the living body, and thus the pharmaceutical composition containing the same as an active ingredient can be useful as a pharmaceutical composition for preventing or treating liver disease, such as acute hepatitis C, chronic hepatitis C, cirrhosis, or hepatocellular carcinoma, caused by C-type virus.

Synthesis and biological activity of novel L-amino acid based analgesic compounds

Synthesis and analgesic activity studies of a series of L-amino acid based compounds were described. These compounds were designed as potential N-type Calcium Channel Blockers and their structures were confirmed by 1H NMR and ESI-MS spectra. Some of the compounds exhibited significant analgesic activity in Mouse Hot-Plate tests. According to the data of pharmacological experiments, we carried out preliminary structure-activity studies and the results indicated that this kind of compounds was useful for the development of new analgesic drugs.

NEW ADAMANTANE DERIVATIVES AS DIPEPTIDYL, PEPTIDASE IV INHIBITORS, PROCESSES FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

The present invention relates to dipeptidyl peptidase IV (DPP-IV) inhibitors of the formula (A): wherein R1, R2, Y, and n are as defined herein, pharmaceutical compositions containing the same, processes for their preparation, and methods for treating disorders mediated by DPP-IV inhibition, such as diabetes, especially Type II diabetes, with them.

NOVEL DIPEPTIDYL PEPTIDASE IV INHIBITORS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND PROCESS FOR THEIR PREPARATION

The present invention relates to novel compounds useful as dipeptidyl peptidase IV (DPP-IV) inhibitors of the formula: (I) wherein Y is -S(O)m, -CH2-, CHF, or -CF2; m is 0, 1, or 2; X is a bond, C1-C5 alkyl (e.g., -CH2-), or -C(=0)-; the dotted line [----] in the carbocyclic ring represents an optional double bond; R1 is substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocyclic ring, substituted or unsubstituted heterocyclylalkyl, substituted or unsubstituted heteroarylalkyl, CN, -COOR3, CONR3R4, -OR3, -NR3R4, or NR3COR3; R2 is hydrogen, cyano, COOH, or an isostere of a carboxylic acid (such as SO3H, CONOH, B(OH)2, PO3R3R4, SO2NR3R4, tetrazole, -COOR3, -CONR3R4, NR3COR4, or -COOCOR3).

NOVEL DIPEPTIDYL PEPTIDASE IV INHIBITORS; PROCESSES FOR THEIR PREPARATION AND COMPOSITIONS THEREOF

The present invention relates to novel dipeptidyl peptidase IV (DPP-IV) inhibitors or general formula (1) useful for treating diabetes, non-insulin dependent diabetes mellitus, impaired glucose tolerance, inflammatory bowel disease, ulcerative colitis,Chron’s disease, obesity, and metabolic syndrome.

Inhibitors of α4β1 mediated cell adhesion

The present invention relates to compound of formula (I), that are potent inhibitors of α4β1mediated adhesion to either VCAM or CS-1 and which could be useful for the treatment of inflammatory diseases. Specifically, the molecules of the present invention can be used for treating or preventing α4β1adhesion mediated conditions in a mammal such as a human. This method may comprise administering to a mammal or a human patient an effective amount of the compound or composition as explained in the present specification.

Design, synthesis, and pharmacological evaluation of new farnesyl protein transferase inhibitors

New CA1A2X peptidomimetics are described as Ras farnesyl transferase inhibitors (FTIs). They include cysteine and methionine as mimetics of the C-terminus sequence of farnesylated proteins. Furthermore, cysteine was replaced by heter